JP2019529476A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2019529476A5 JP2019529476A5 JP2019516536A JP2019516536A JP2019529476A5 JP 2019529476 A5 JP2019529476 A5 JP 2019529476A5 JP 2019516536 A JP2019516536 A JP 2019516536A JP 2019516536 A JP2019516536 A JP 2019516536A JP 2019529476 A5 JP2019529476 A5 JP 2019529476A5
- Authority
- JP
- Japan
- Prior art keywords
- cancer
- cabozantinib
- urinary tract
- cell carcinoma
- pharmaceutically acceptable
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Withdrawn
Links
Applications Claiming Priority (9)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201662400481P | 2016-09-27 | 2016-09-27 | |
| US62/400,481 | 2016-09-27 | ||
| US201762457952P | 2017-02-12 | 2017-02-12 | |
| US62/457,952 | 2017-02-12 | ||
| US201762459340P | 2017-02-15 | 2017-02-15 | |
| US62/459,340 | 2017-02-15 | ||
| US201762552296P | 2017-08-30 | 2017-08-30 | |
| US62/552,296 | 2017-08-30 | ||
| PCT/US2017/053766 WO2018064191A1 (en) | 2016-09-27 | 2017-09-27 | Method of treating urothelial carcinoma and other genitourinary malignancies using n-(4-(6,7-dimethoxyquinolin-4-yloxy)-phenyl)-n'(4-fluorophenyl)cyclopropane-1,1-dicarboxamide |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2019529476A JP2019529476A (ja) | 2019-10-17 |
| JP2019529476A5 true JP2019529476A5 (enExample) | 2020-11-12 |
Family
ID=60190916
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2019516536A Withdrawn JP2019529476A (ja) | 2016-09-27 | 2017-09-27 | Ｎ−（４−（６，７−ジメトキシキノリン−４−イルオキシ）フェニル）−ｎ’−（４−フルオロフェニル）シクロプロパン−１，１−ジカルボキサミドを用いた尿路上皮癌及び他の尿生殖器悪性腫瘍の治療方法 |
Country Status (7)
| Country | Link |
|---|---|
| US (2) | US20210275515A1 (enExample) |
| EP (1) | EP3518928A1 (enExample) |
| JP (1) | JP2019529476A (enExample) |
| AU (1) | AU2017336547A1 (enExample) |
| CA (1) | CA3038500A1 (enExample) |
| MA (1) | MA46355A (enExample) |
| WO (1) | WO2018064191A1 (enExample) |
Families Citing this family (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA3052670A1 (en) | 2017-03-01 | 2018-09-07 | Genentech, Inc. | Diagnostic and therapeutic methods for cancer |
| GEAP202415420A (en) | 2018-01-26 | 2024-12-25 | Exelixis Inc | Compounds for the treatment of kinase-dependent disorders |
| CN120305263A (zh) | 2018-06-15 | 2025-07-15 | 汉达癌症医药责任有限公司 | 卡博替尼的盐类于制备治疗癌症的剂型的用途 |
| AU2019361983A1 (en) * | 2018-10-18 | 2021-05-20 | Genentech, Inc. | Diagnostic and therapeutic methods for sarcomatoid kidney cancer |
| BR112023001792A2 (pt) * | 2020-07-31 | 2023-04-11 | Exelixis Inc | Combinações para o tratamento de câncer |
| CA3202761A1 (en) * | 2020-11-25 | 2022-06-02 | Nanocopoeia, Llc | Amorphous cabozantinib particles and uses thereof |
| WO2022177983A1 (en) * | 2021-02-19 | 2022-08-25 | Slayback Pharma Llc | Pharmaceutical compositions of cabozantinib |
| US20220387418A1 (en) * | 2021-02-19 | 2022-12-08 | Slayback Pharma Llc | Pharmaceutical compositions of cabozantinib |
| US20220362235A1 (en) * | 2021-02-19 | 2022-11-17 | Slayback Pharma Llc | Pharmaceutical compositions of cabozantinib |
| US20220280500A1 (en) * | 2021-02-19 | 2022-09-08 | Slayback Pharma Llc | Pharmaceutical compositions of cabozantinib |
| AU2024215796A1 (en) | 2023-01-31 | 2025-05-15 | Handa Oncology, Llc | Improved cabozantinib compositions and methods of use |
Family Cites Families (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA2744997A1 (en) | 2003-09-26 | 2005-04-07 | Exelixis, Inc. | C-met modulators and method of use |
| US20080200515A1 (en) | 2006-12-29 | 2008-08-21 | Tap Pharmaceutical Products Inc. | Solid state forms of enantiopure ilaprazole |
| WO2012009722A1 (en) | 2010-07-16 | 2012-01-19 | Exelixis, Inc. | C-met modulator pharmaceutical compositions |
| TWI640509B (zh) | 2011-02-10 | 2018-11-11 | 艾克塞里克斯公司 | 製造喹啉化合物之方法及包含該化合物之醫藥組合物 |
-
2017
- 2017-09-27 JP JP2019516536A patent/JP2019529476A/ja not_active Withdrawn
- 2017-09-27 AU AU2017336547A patent/AU2017336547A1/en not_active Abandoned
- 2017-09-27 MA MA046355A patent/MA46355A/fr unknown
- 2017-09-27 WO PCT/US2017/053766 patent/WO2018064191A1/en not_active Ceased
- 2017-09-27 CA CA3038500A patent/CA3038500A1/en not_active Abandoned
- 2017-09-27 EP EP17791484.3A patent/EP3518928A1/en not_active Withdrawn
- 2017-09-27 US US16/336,724 patent/US20210275515A1/en not_active Abandoned
-
2022
- 2022-11-29 US US18/059,840 patent/US20230130243A1/en not_active Abandoned
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2022022264A5 (enExample) | ||
| JP2017039771A5 (enExample) | ||
| JP2022031403A5 (enExample) | ||
| AU2021307410A1 (en) | Combination therapy for treating abnormal cell growth | |
| JP2022533578A5 (enExample) | ||
| JP2015534579A5 (enExample) | ||
| JP2015534578A5 (enExample) | ||
| KR20240041978A (ko) | 비정상적 세포 성장을 치료하기 위한 조합 요법 | |
| JP2017537105A5 (enExample) | ||
| CN101969931A (zh) | 包含霉酚酸的调节释放药物组合物及其方法 | |
| CN101669941B (zh) | 一种联合用药治疗恶性肿瘤的方法以及抗恶性肿瘤的药物 | |
| Pietrzak et al. | Oral and transdermal hormonal contraception in women after kidney transplantation | |
| JP2021502415A (ja) | 癌の処置のためのアパチニブを用いる併用療法 | |
| JP2022523530A5 (enExample) | ||
| CN105873583A (zh) | 用于降低慢性肾病患者的心力衰竭的枸橼酸铁 | |
| EP3518928A1 (en) | Method of treating urothelial carcinoma and other genitourinary malignancies using n-(4-(6,7-dimethoxyquinolin-4-yloxy)-phenyl)-n'-(4-fluorophenyl)cyclopropane-1,1-dicarboxamide | |
| WO2018072743A1 (zh) | Pd-1抗体与ido抑制剂联合在制备抗肿瘤的药物中的用途 | |
| WO2023061472A1 (zh) | 抗her2抗体药物偶联物和酪氨酸激酶抑制剂联合在制备治疗肿瘤的药物中的用途 | |
| CN116712539A (zh) | 抗her2抗体药物偶联物和抗pd-1抗体联合在制备治疗肿瘤的药物中的用途 | |
| JP2012525358A5 (enExample) | ||
| CN109663145A (zh) | 一种碘油靶向药物复合物 | |
| Alfonso et al. | Previous gastric bypass surgery complicating total thyroidectomy. | |
| CN110545803A (zh) | 用于淋巴结阳性、早期、激素受体阳性、人表皮生长因子受体2阴性乳腺癌的辅助治疗的内分泌疗法和abemaciclib组合 | |
| JP2020512292A5 (enExample) | ||
| Jin et al. | Apatinib monotherapy for advanced VEGFR-2-negative nasopharyngeal carcinoma: A case report |